New News

One of the First Publicly-Traded Psychedelic Wellness Companies is Mapping the Mental Health Revolution


It took decades of cultural change combined with legislative progress and growing commercial viability to bring the widespread use of cannabis and its derivatives to the American consumer.

Closely following the heels of “Mary Jane” are “Lucy and Molly,” as overwhelming evidence of the use of psychedelics and psychedelic-assisted psychotherapy as treatment for the worst types of mental health disorders has prompted some employers to go public. psychedelic enterprises, despite the fact that only Oregon has legalized private possession of psilocybin mushrooms.

With a background in business and marketing, Matt Stang, now founder and CEO of Delic Holdings, took over High Times Magazine 18 years ago as part of a long journey to the forefront of the effort to legalize cannabis.

Matt and Jackee Stang

“After the overwhelming response in the United States to legalization in the 2016 and 2020 elections, where cannabis has really taken over and flipped to the point where you don’t have to put that genie back in the bottle, we begin to focus on what we think. are the next tipping points: psychedelics, “Stang said. GNN In an interview.

Matt bought a number of ketamine infusion treatment centers in California and started Delic with his wife Jackee in hopes of having a roadmap ready for when the US states will inevitably begin to allow, at least from the point of view. From a medical point of view, the use of these substances. Its centers, the company’s main assets, have been operating for 15 years, have generated $ 1.5 million in revenue, and have conducted more than 4,000 courses of treatment.

“When we created it two years ago, there was no ‘psychedelic corporation,’ so people thought we were a little crazy,” says Stang. “We believe that similar pathways have been opened for cannabis that will help psychedelics go down a much faster path.”

Unsurpassed results

Stang firmly believes that the last 20 years of research on the use of psychedelics and assisted therapies for things like treatment-resistant depression, post-traumatic stress disorder, childhood trauma, and more are undeniable for anyone who really wants to help people. people who need it.

In fact, the Johns Hopkins Center for Psychedelic Research has demonstrated therapeutic success rates rarely or never achieved with traditional antidepressants. Their most recent study found that 67% of trial participants who used psilocybin-assisted psychotherapy had a 71% reduction in treatment-resistant depression after a four-week follow-up.

“The magnitude of the effect we saw was about four times greater than what clinical trials have shown for traditional antidepressants on the market,” Alan Davis, Ph.D., professor of psychiatry and behavioral sciences who participated in the study, has saying.

Ketamine, used by Stang in his clinics, is the only psychedelic approved by the FDA for use as a mental health enhancer.

“The amazing power of these substances to help with PTSD and trauma puts you squarely in the veteran’s lap,” explains Stang. “You know I’ve seen veterans who have gone for ketamine treatments … I saw a giant bear man at a clinic in San Diego who was crying, and he said [without these treatments] ‘I would not be alive, I would not have my family.’

MDMA-assisted psychotherapy for veterans by the Multidisciplinary Association for Psychedelic Studies (MAPS) is currently in expanded phase III FDA trials as a “revolutionary therapy”. It is expected to be available in 2023.

Although not related to depression, Johns Hopkins has also studied MDMA Y even the much talked about DMT, called the “Molecule of the Spirit” by a documentary maker. Their results found interesting effects, such as an increase in overall satisfaction with life by 89% of the latter, and neurological reactivation of critical learning pathways with the former.

From gray to white

As strong as the science is and as wonderful as the results, the cannabis campaigns proved that until there is tax revenue, states will not take drug legalization very seriously.

As one of the first publicly traded psychedelic-related corporations, Matt and Jackee’s hopes with Delic are to create a distributive and educational entity that immediately provides thousands of people with a place to safely shop for quality products and obtain the better information on where psychedelic wellness lies. are the centers.

“For us, going public was both an opportunity to allow people to participate in the nascent psychedelic revolution, as well as a great opportunity to help use public capital to build a real, long-term cash flow generating business,” says Stang. GNN.

WATCH: Magnetic brain treatment was found to alleviate depression in 90% of participants without negative side effects

“What I’ve seen doing this for almost 20 years in cannabis is that when a gray market turns white, having a platform to define best-in-class is probably the most important thing because people don’t know what they’re looking for. They just know that something is happening that is changing the world. “

CHECK OUT: Another study shows that psychedelic psilocybin mushrooms offer long-term relief from depressive symptoms

Expanding the line of ketamine clinics, Delic is in talks with a company that has designed the first medically licensed vaping platform for psilocybin, to deliver a single dose of the compound that gives magic mushrooms their magic, in a familiar way. for those. who vape with cannabis.

Other products would include a nanoencapsulation delivery method that allows psilocybin to bypass absorption in the liver and remain in the blood where it becomes much more bioavailable, allowing for faster transmission of the experience that could perhaps reach different pathways in the brain. , thus expanding the range of treatable regions.

RELATED: As the UN reclassifies cannabis, landmark study shows CBD does not impair driving

Both are in development and would require a laboratory and legal landscape to exist before either could increase Delic’s market share.

Delic also does grassroots organizing and lobbying, with Stang repeatedly citing the 2022 midterm elections as a key time to see compounds like psilocybin, MDMA and others on the ballot in progressive states.

PLUS: Are you having trouble sleeping? New Research Says a Saffron Dose May Help You Snooze

Since the mental and behavioral health consequences of the 2020-2021 lockdown seasons have yet to reveal their true extent, the need for safe legal products and treatments with these compounds could be greater than ever, and like all good ones entrepreneurs, Stang is anticipating where the demand will be.

SEND this story bumping into friends by sharing it on social media …



You may also like

Comments are closed.

More in:New News